Lodoco® (colchicine) – New drug approval
June 20, 2023 - Agepha Pharma announced the FDA approval of Lodoco (colchicine), to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular (CV) death in adult patients with established atherosclerotic disease or with multiple risk factors for CV disease.
Top